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Masashi Mizuno*, Yasuhiro Suzuki, Fumiko Sakata and Yasuhiko ItoAbstract
This review article is an invited review by both the Japanese Society for Dialysis Therapy (JSDT) and Japanese
Society for Peritoneal Dialysis (JSPD).
Automated peritoneal dialysis (APD) using a cycler machine is an alternative choice for patients who are on
peritoneal dialysis (PD) for the treatment of end-stage renal disease (ESRD). The main purpose is to allow more
free time and an improved quality of life for PD patients versus continuous ambulatory PD (CAPD). However,
it remains unclear which modality is a better choice, especially with regard to the induction period of PD,
due to a lack of research. When we propose PD therapy to ESRD patients, in addition to the obvious benefit
of more free time, we also need to consider the advantages and disadvantages with regard to each patient’s
medical comorbidities, physical condition, social activities, psychological readiness, and medical economics.
In this review, we attempted to determine which method is more advantageous overall, APD or CAPD.
In conclusion, it is important to consider the medical, social, physical, and economic aspects for each
PD patient as well as patient preference when helping patients choose between APD and CAPD.
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This review article is an invited review by both the
Japanese Society for Dialysis Therapy (JSDT) and
Japanese Society for Peritoneal Dialysis (JSPD).
Automated peritoneal dialysis (APD) was introduced
in the 1960s using concepts that are similar to current
methods. To perform peritoneal dialysis (PD) in patients
with end-stage renal failure (ESRD), peritoneal puncture
was essential for the insertion of a cannula to access the
abdominal cavity each time a patient presented for dialy-
sis, until the development of the silicon-based Tenckhoff
catheter introduced by Henry Tenckhoff in 1968 [1].
Therefore, peritonitis occurred very frequently and
prevented clinical use of continuous long-term PD
therapy. Boen et al. reported that APD was performed
intermittently with the use of huge amounts of PD fluid
(PDF) [2]. To induce APD, large 12-gal (close to 45 L)
glass bottles of PDF were required for the automatic* Correspondence: mmizu@med.nagoya-u.ac.jp; masashim1jp@yahoo.co.jp
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APD therapy enjoyed more free time as it allowed for
the exchange of larger amounts of fluid over shorter
periods of time; thus, dialysis could be performed inter-
mittently (once every 3 or 4 days). Moreover, patients
experienced less frequent episodes of peritonitis.
In 1972, Tenckoff et al. proposed a much simpler
APD system that was more compact and attached to a
reverse osmosis unit to eliminate the need for huge
bottles [3], and the Drake-Willock PD cycler machine
was developed with a reverse osmosis system [4]. The
development of the Tenckhoff catheter allowed perma-
nent access to the peritoneal cavity. Glass bottles for
containment of PDF evolved into plastic bags that
continue to be used today [5]. Because of the induction
of continuous ambulatory PD (CAPD), PD therapy
became safer and ESRD patients were completely
released from bedrest in the hospital and had greaterle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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crease in peritonitis and gastrointestinal injuries caused by
repeated puncture with a PD cannula. After that, a system
was developed similar to present-day APD. In the 1980s,
the automated peritoneal dialysis cycler machine, Pac-X
(Baxter Limited, Tokyo, Japan), was introduced worldwide
[6] and was also used as a primary cycler for APD in Japan,
followed by the Pac-X cycler II (Baxter, Fig. 1a). The
Quantum PD dialysis machine (Baxter), a simple auto-
matic bag change system that could perform only one bag
change per night, was also used to support nocturnal
dialysis regimens in Japan (Fig. 1b). Now, we can choose
from four types of much more compact cycler machines
from four different PD companies (Fig. 2).
When cycler machine-operated APD was introduced,
its greatest advantage was a larger selection of PD
treatments options, including continuous cycling PD
(CCPD) (Fig. 3), and different types of dialysate solu-
tions could also be mixed in a cycler machine. In the
present method of APD, the cycler machine is also
advantageous because of the decreased frequency of
PDF bag changes needed. Currently, a standardized
APD selection does not exist in Japan. Unfortunately,
there are a few studies originating in Japan for suppor-
ting the use of APD. Therefore, the decision to select
induction of APD is often influenced by experiences
and preferences of physicians, patients, and/or care-
givers. Thus, the question remains, is it better to choose
CAPD or APD for patients? In this review, we refer to
previous reviews and recent reports and summarize the
advantages and disadvantages with regard to medical,a b
Fig. 1 Earlier-generation machines that have supported automated
peritoneal dialysis (APD) in Japan. Before recent models of cyclers,
there were several commercially based machines. a Pax-X cycler II
and b Quantum PD dialysis machine. The two types of APD machines
were purchased by Baxter Japan and are commonly used in Japan
(photo frames courtesy of Baxter Limited (Tokyo, Japan))socioeconomic, and psychological aspects of care when
choosing the best APD system.Which is more medically advantageous to
patients with ESRD: APD or CAPD?
Prognosis for life survival and/or technical survival
In a recent review article summarizing reports concern-
ing life survival and technical survival before 2011 [7],
most showed no significant difference between APD and
CAPD, except for a retrospective cohort study that dem-
onstrated APD to be more advantageous [8]. Another
report that analyzed long-term survival showed CAPD
and APD to be similar [9].
After 2011, it has also been reported that there is no
difference in life survival and technical survival between
APD and CAPD in Hong Kong in 2013 [10]. In contrast,
it was reported that technical survival of APD patients is
better than for CAPD patients, even if death was excluded
as a reason for technical failure, in the UK in 2011 [11]. In
a recently published prospective and large-scale national
cohort study in Brazil in 2015, technical survival was not
different between APD and CAPD, although life survival
was better in APD than CAPD [12].
Of note, an interesting report showed that PD patient
survival in those in the high transporter category on
the peritoneal equilibration test (PET), which is usually
performed as an assessment of peritoneal membrane
function in PD patients, was better with APD than with
CAPD [13]. This finding might support the assumption
that frequent PD bag changes with APD could improve
total ultrafiltration in PD patients in the high transporter
category on the PET. In contrast, survival in those patients
in the low transporter category on the PET was reported
to be poorer with APD than with CAPD in that study.
As a brief summary, patient survival and technical
survival with regard to PD therapy may be similar between
APD and CAPD, although a few reports have shown
advantages of APD usage, especially in PD patients in the
high transporter category on the PET. Summary is shown
in Table 1.Adequacy of dialysis of creatinine and blood urea
nitrogen between APD and CAPD
Theoretically, adequacy of dialysis of creatinine and blood
urea nitrogen (BUN) is dependent on the frequency of
bag changes, dwell time, and amount of PDF. Therefore, it
is difficult to compare APD and CAPD. When CAPD
therapy is considered in patients with a large body mass
with ESRD and who have no residual renal function
(RRF), five or more bag changes may be required [14].
Therefore, induction of APD is useful to decrease the
number of PD bag changes in those patients. On the
other hand, in several reports concerned with the
a b
c d
Fig. 2 Recent modern cycler machines for automated peritoneal dialysis delivered from four companies in Japan. In Japan, four
companies delivered four different cycler machines, respectively, a the “home APD system YUME,” which was purchased by Baxter
(Tokyo, Japan), b the “My Home PICO APD® system,” which was purchased by TERUMO Co. (Tokyo, Japan), c the “APD system
PD-Mini Neo” which was purchased by JMS Co. (Tokyo, Japan), and d the “Sleepsafe® APD system” which is purchased by




Fig. 3 Various schedules of dwell time in peritoneal dialysis (PD) to help select modalities of PD. Typhical pattern of continuous
ambulatory PD is shown in a. We have the ability to select various options for PD menus after induction of automated PD (APD), which
are shown in b. Flexibility in the PD menu allows for adjustment to various lifestyles of PD patients in addition to managing the increase in
total PD volume for adequacy of dialysis and shortening each dwell time for enough ultrafiltration. As an alternative methods, tidal PD was a choice of PD
(c). Solid orange area shows dwells of the cyclers. CCPD continuous cyclic peritoneal dialysis, TAPD tidal automated peritoneal dialysis, NPD nocturnal PD
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Table 1 Studies of comparison between APD and CAPD for life survival and/or technical survival
Study (published year)
[reference]
Study design Setting countries Data source N (CAPD, APD) Duration of observation Results




Netherland 1988–1991) Single center 82 (41, 41) 24 months Ns.




USA (1999, 2000, 2001) Multicenter >30000 (N/A) N/A APD is better within
1 year after PD induction
Badve SV et al. (2008)
[86]




4128 (2393, 1735) 5 years Ns.




Taiwan (1996–2005) Single center 270 (188, 82) 6 months Ns.




Mexico (2003–2005) Single center 237 (139, 98) 2 years APD is better
Mehrota R et al. (2009)
[88]
National registry USA (1996–2004) Multicenter
(USRDS)
66381 (42942, 23439) 2~10 years Ns.








649 (562, 87) 5 years Ns.
Johnson DW et al. (2010)
[13]




3 months to 10 years Ns. Fatal risk was
decreased in H Category




UK (2003–2008) Single center 372 (178, 194) 5 years APD was better
for survival




USA (2001–2008) Multicenter 620 (179, 441) 3 month–7 years APD was better




Taiwan (1997–2008) Single center 282 (121, 161) 3 months–10 years APD was better






Multicenter 270 (180, 90) 9.5 months–46.5 months Ns.




Brazil (2004–2011) Multicenter 2890 (1445, 1445) 5 years Life survival of APD was
better than that of CAPD.
Ns. for technical survival




Japan (2010–2012) Multicenter 200 (119, 81) 3 years Ns.
Ref. Bieber SD et al. [7]
Ns. significant differences between CAPD and CAD, N/A not available in the text, ANZDATA Australia and New Zealand Dialysis and Transplant, NECOSAD Netherlands Cooperative Study on the Adequacy of Dialysis,
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CAPD [15, 16], no significant difference was reported.
Removal of sodium, phosphate, or macromolecules
Using a glucose-based PDF, adjustment of body volume
is one reason to choose APD [14] because the usage of a
cycler machine can perform frequent and short-term
changes of dialysate to obtain appropriate ultrafiltration.
However, we also have to consider sodium removal with
ultrafiltration because sodium sieving sometimes occurs,
especially when using high-concentrated glucose PDF
for a short dwell time [17, 18]. Sodium sieving, first pro-
posed by Rodriguez-Carmona et al., suggests that water
removal is faster than sodium removal through ultra-
small pore (aquaporin-1) water channels [18]. In fact,
there were a couple of reports showing that total sodium
removal in patients on CAPD was more than that on
APD, although total ultrafiltration on CAPD might be
less than that on APD [14, 18]. When Nakayama et al.
reported the comparison of the efficacy of sodium removal
among different concentrations of glucose-based PDFs
with conventional sodium or low sodium concentration
[17], sodium sieving was clearly observed in PD patients
using high-concentrated glucose-based PDF over a short
dwell time. Therefore, using high-glucose-concentrated
dialysate and frequent bag changes with a short dwell
time; removal of sodium might not be sufficient because
of sodium sieving. In that case, ideally, options to remove
an appropriate amount of sodium include increasing dwell
time, combining with usage of icodextrin, not using high-
glucose dialysate, extending the dwell time of the cycler
machine’s program, and/or decreasing sodium intake [19].
Concerning the removal of large molecules of uremic
toxin, it has been reported that the efficacy of CAPD
is better than that of APD for the removal of β2-
microglobulin [20–23].
Therefore, the efficacy of the removal of sodium and
large uremic molecules is better in CAPD patients with
a long dwell time than in APD patients with frequent
and short dwell times.
Effects for RRF
Preservation of residual renal function (RRF) is important
to prevent lethal cardiovascular events in ESRD patients.
It would be better to focus efforts on maintaining RRF in
ESRD patients, even if they have chosen maintenance
blood purification therapies, including hemodialysis [24].
In PD patients, it has been shown that life survival is
better when the rate of decline in RRF is slower [25] and
that preservation of RRF is an important factor in decrea-
sing the risk of cardiovascular death [26]. In addition, PD
patients who have chosen incremental PD might have
better control of body fluid volume and removal of macro-
molecules, including preservation of RRF [27]. Therefore, itis important to make an effort to prevent factors that
worsen RRF such as cautiously using large doses of loop
diuretics, avoiding nephrotoxic drugs, minimizing use of
frequent radiocontrast dyes, optimizing blood pressure
control, using an angiotensin-converting enzyme inhibitor
or angiotensin receptor blocker, avoiding hypotension and
dehydration, selecting a biocompatible PD solution and/
or icodextrin-based PD solution, and preventing PD-
related peritonitis [28–30]. As part of incremental PD,
low-frequency APD may be a good choice for ESRD
patients [31].
However, it has been controversial whether APD or PD
is better for preservation of RRF. Several cohort studies
have approached this question. Recently, Bieber et al.
summarized 20 cohort studies to compare the preservation
of RRF between APD and CAPD in literature published
between 1994 and 2011 [7], and most of them showed no
differences in preservation of RRF between APD and
CAPD. In 2015, when usage of APD was started from
induction periods for 24 months, the decrease in RRF with
APD was reported to be faster than that with CAPD in a
multicenter cohort study from a Spanish group [32].
There were generally no differences in the method
used for PD between APD and CAPD in most of the
literature, but some results showed a slight advantage in
the preservation of RRF for CAPD patients. One reason
APD might be slightly less advantageous than CAPD,
especially during induction periods, is the shorter dwell
time and more frequent changes of PDF, which may
result in excessive dehydration in patients on APD. Past
reports are summarized in Table 2.
Effects on incidence/recovery of PD-related peritonitis
This point has also been controversial until now (Table 3).
Briefly, APD may be better, or at least no worse, as far as
the incidence of peritonitis compared with CAPD. In a
meta-analysis [33], the incidence of peritonitis in patients
with APD was lower than those with CAPD because the
frequency of PD bag changes in APD was less than in
CAPD, meaning that opportunities for contamination in
APD were fewer. In contrast, there were several reports
that showed no differences in the incidence of peritonitis
between APD and CAPD [11]. In another review article,
Bieber et al. summarized seven reports that compared the
incidence of peritonitis between APD and CAPD. The
review showed that three of the reports demonstrated no
differences between APD and CAPD, two found APD to
be more advantageous compared to CAPD, and one
showed advantages of CAPD over APD before 2011 [7]. In
a recent multicenter cohort report in Hong Kong [10],
peritonitis-free survival in patients on APD was better than
peritonitis-free survival in patients on CAPD for up to
2 years after starting PD therapy. Peritonitis-free survival
was defined as the duration of PD until first occurrence of
Table 2 Comparison between APD and CAPD for preservation of residual renal function
Study (published year) Study design Setting countries Data source N (CAPD, APD) Duration of observation Results






Single 81 (41, 41) 24 months Ns.




Japan (1992–1994) Single center 18 (5, 13) 6 months CAPD was better




Denmark (1995–1999) Multicenter 34 (17, 17) 6 months Ns.




France (1995–1997) Single center 36 (18, 18) 12 months CAPD was better




Spain (N/A) Single center 20 (11, 9) 12 months Ns.




Japan (N/A) Single 34 (17, 17) 24 months Ns. (but decrease of urinary
volume was faster in CAPD)




USA (1997) USRDS dialysis
morbidity
and mortality
1032 (722, 310) 8–18 months Ns.




Canada (1994–1997) Single center 242 (211, 31) 27 ± 14 months Ns.




USA (1991–2000) N/A 184 (70, 114) <9 months Ns.




Japan (1995–2001) Single center 34 (27, 7) 12~42 months CAPD was better




Australia (1995–2001) Single center 146 (134, 12) 21 ± 15 months Ns.









UK (2003–2008) Single center 277 (130, 147) 5 years Ns.




UK (2001–2008) Multicenter 620 (179, 441) 450 days Ns.






583 (505, 78) 3 months–3 years Ns.




Poland (1992–2009) Multicenter 101 children (44, 57) 36 months CAPD was better




Spain (2000–2010) Multicenter 493 (365, 125) 6–24 months CAPD was better when
APD was introduced during
induction period of PD
Ref. Bieber SD et al. [7]












Table 3 Comparison for effects on incidence of PD-related peritonitis between APD and CAPD
Study (published year) Study design Setting countries Data source N (CAPD,APD) Duration of observation Results
Alliapoulos JC et al.
(1984) [102]
Cross-sectional study USA (N/A) Single center 10 pediatric patients
and subsequently CCPD.
15.0 ± 2.8 months for
CAPD vs. 9.3 ± 3.2 months
Ns.




Netherlands (1988–1991) Single center 82 (41, 41) 24 months APD was better




Denmark (1995–1999) Multicenter 34 (17, 17) 6 months 2 cases for CAPD,
1 case for APD
Rodríguez-Carmona A et al. (1999) [103] Prospective
nonrandomized study
Spain (1989–1998) Single center 328 (213, 115) 3 months–10 years APD was better




USA (1990–2000) Multicenter 583 (384, 199) N/A Ns.
Oo TN et al. (2005)
[105]





UK (2002–2003) Multicenter 863 (538, 325) at the
end of 2002, (635, 445)
at the end of 2003
2 years APD was better




Canada (1996–2005) Multicenter 3180 (N/A) N/A Ns.
Balasubramanian G et al. (2011) [11] Retrospective
observational study
UK (2003–2008) Single center 372 (178–194) 5 years APD was better




Netherlands (1993–2007) Single center 205 (112, 93) 14 years Ns.




Japan (2005–2007) Multicenter 561 (N/A) N/A Ns.




Korea (1986–2011) Single center 57 (51, 6), less than
18 years old
6 months–240 months APD was better in
childhood




Hong Kong (1995–2011) Multicenter 270 (180, 90) 9.5 months–46.5 months APD was better for
induction period
of PD




Japan (2001–2011) Single center 192 (156, 36) 10 years Ns.








6959 (2761, 4198) Mean 1.9 years Ns.




Brazil (2004–2011) Multicenter 2890 (1445, 1445) 5 years Ns. for time to first
episode of peritonitis




Japan (2010–2012) Multicenter 200 (119, 81) 3 years Ns.
Ref. Bieber SD et al. [7]
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and CAPD were reported with regard to the incidence of
peritonitis [34]. Our recent reports also showed no diffe-
rences between APD and CAPD [35].
Concerning the prognosis of PD-related peritonitis, it
has been reported that a difference between APD and
CAPD has not been observed [36]. In considering whether
to continue using a cycler during treatment for PD peri-
tonitis, the possible selection of antibiotics in APD was
limited by the 2010 ISPD guideline [37–39], compared
with CAPD therapy. However, when PD-related peritonitis
occurs in patients treated with APD, we can transiently
change the method of treatment from APD to CAPD until
the patient recovers from peritonitis. Of note, it is impor-
tant to keep in mind the possible difficulty in observing
and recognizing slightly cloudy PDF in the early stage of
peritonitis in APD therapy because the waste fluid tank
might be easily soiled by the drainage of PDF.
From the past literature, it has been suggested that the
decrease in the number of PDF bag changes might
decrease opportunities for peritonitis caused by conta-
mination in patients with APD. Especially during the
early period of PD induction, APD might be associated
with a lower incidence of peritonitis than CAPD. How-
ever, it remains unclear which method, APD or CAPD,
is associated with an overall lower incidence of perito-
nitis. Large-scale prospective cohort studies might be
required in the future to more clearly determine whether
APD or CAPD is better.
Effects associated with peritoneal leakage or herniation
When abdominal pressures are increased, the risks of
incidence of peritoneal leakage and/or herniation, such
as incisional herniation, pericatheter herniation, umbi-
lical herniation, and inguinal herniation, are increased
[40, 41]. It is well known that, in humans, abdominal pres-
sure is the lowest in the supine position and the pressure
increases in the sitting and standing positions [42]. After
starting PD therapy, abdominal pressure in ESRD patients
may increase, depending on the dwell volume of PDF in
the abdomen [42, 43]. It was also reported that abdominal
pressure was increased by coughing and constipation,
which induce excessive straining, and by increased intra-
peritoneal volume of PDF [42]. Although there were some
reports that intraperitoneal pressure was not dependentTable 4 Risk of incidence of peritoneal leakage and/or herniation be
Study
(published year)
Study design Setting countries Data source
Alliapoulos JC et al.
(1984) [102]
Cross-sectional study USA (N/A) Single center







Ns. not significant differences between CAPD and CAD, N/A not available in the texon intraperitoneal volume, the investigated volume was
more than 2 L in these reports [41, 44]. In contrast,
Twardowski et al. reported that abdominal pressure was
observed to increase with the addition of 3 L of fluid to an
empty abdomen [42].
Polycystic kidney disease (PKD) was reported as an inde-
pendent risk factor for peritoneal leakage and herniation in
PD patients [41, 45, 46]. In contrast, there was a report that
showed no increase in the incidence of herniation in PKD
patients [47]. Thus, which type of PD is better to decrease
the risk of herniation in PD patients, APD or CAPD? In
patients with PKD, the incidence of herniation with APD
treatment was less than in patients treated with CAPD [41].
On the other hand, Rabindranath et al. reported that the
risk of herniation was not different between APD and
CAPD in a meta-analysis [33]. Of note, because obesity has
also been reported to increase intra-abdominal pressure
[42, 43], extreme obesity might be a disadvantage to PD
therapy due to the increased risk of peritoneal leakage and/
or herniation.
When abdominal pressure is increased in clinical situa-
tions such as PKD and obesity, one could theoretically
choose to induce APD to prevent the development of
peritoneal leakage and herniation. In fact, there have been
several reports showing that APD had a lower rate of
herniation than CAPD [41, 44], although other reports
have shown no significant difference in the incidence of
herniation with APD versus CAPD [48] (Table 4). How-
ever, the latter reports compared dwell volumes of more
than 2 L. Therefore, it may be useful to maintain only up
to approximately 1 L to prevent an increase in abdominal
pressure and to decrease the risk of peritoneal leakage and
herniation in high-risk patients [49, 50]. A Japanese report
showed that intra-abdominal pressure was not significantly
increased when dwell volume was less than 1 L in Japanese
patients [51]. Because of this data, it may be suggested that
a dwell volume of less than 1 L of PDF will prevent leak-
age/herniation, at least in the Japanese population.
Influences on SAS and respiratory function
Sleep disorders are common complications and factors that
shorten life expectancy for ESRD patients due to the associ-
ated cardiovascular disease [52–55]. Sleep apnea syndrome
(SAS) is a major cause of sleep disorder, hypertension,
arrhythmias, and sudden death [56, 57]. Furthermore,tween APD and CAPD
N (CAPD, APD) Duration of observation Results
10 pediatric patients
and subsequently CCPD
15.0 ± 2.8 months for
CAPD vs. 9.3 ± 3.2 months
CAPD was higher
risk than APD but Ns
80 (72, 8) 62 with
both modalities
5 years CAPD was higher
risk than APD but Ns
t
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apnea/hypopnea episodes per hour of sleep was suppressed
by induction of APD compared with CAPD [58]. They
especially mentioned that APD might be more effective for
obstructive apnea/hypopnea when SAS is diagnosed in PD
patients. However, Sydney et al. reported that SAS was an
independent risk factor for subsequent mortality and car-
diovascular events when ESRD patient had SAS at the start
of PD [59]. Diagnosis and subsequent therapy may be
required to decrease mortality.
With regard to respiratory disease, which type of PD
therapy is a better choice for patients with severe pulmo-
nary disease, APD or CAPD? It is thought that PD is
relatively contraindicated in ESRD patients with severe
pulmonary disease [60, 61]. In contrast, some reports have
shown that induction of CAPD did not worsen respiratory
function [62, 63]. It is therefore not certain which is better,
APD or CAPD, in ESRD patients with severe pulmonary
disease. A position change from sitting to supine position
was reported to decrease 10 % of functional residual
capacity and increase closing volume under CAPD the-
rapy [63, 64]. It might be suggested that APD is better
than CAPD in severe pulmonary disease, although it is
still unclear whether or not it might be suitable to select
PD as renal replacement therapy.
Which is more suitable, APD or CAPD, to improve
health-related QoL in physical, psychological, and
social activity?
Effects for health-related QoL
We believe that current treatment with induction of APD
can relieve PD patients from rushing to perform repeated
daily bag changes, thus allowing more free time. It was
expected that APD might be better than CAPD with
regard to physical, psychological, and/or social activities ofTable 5 Comparison between APD and CAPD for health-related qu
Study (published year) Study design Setting countries Data











Sunder S et al. (2008) [68] Prospective
observational study
India (N/A) Sing
Guney I et al. (2010) [65] Cross-sectional study Turkey (N/A) Sing




















Ref. Bieber SD et al. [7]
Ns. not significant differences between CAPD and CAD, N/A not available in the texPD patients. Some studies were evaluated using mental
composite scores and physical composite scores in the
comparison of APD and CAPD. Surprisingly, most pub-
lished reports, including prospective cohort studies and
RCT studies, showed no significant differences in health-
related quality of life (QoL) or depression in PD patients
treated with either APD or CAPD [11, 65]. In a review
published by Bieber et al. in 2014, several of those reports
concerning health-related QoL were summarized [7].
They described that the health-related QoL of ESRD
patients was not different between APD and CAPD. For
QoL of caregivers, APD might be better than CAPD [66]
(Table 5).
Quality of sleep for APD
Disturbance of sleep might occur more frequently with
APD than with CAPD. One reason may be the cycler’s
loud beeping to alert PD patients. The alert is necessary to
wake up PD patients in order to resolve any trouble and
continue APD therapy. However, although one might
expect APD to decrease the quality of sleep [16, 65], there
were no significant disadvantages of APD noted with
regard to sleep disorders compared to CAPD in previous
reports [7, 67, 68]. In fact, both APD and CAPD may
equally worsen poor sleep quality [65].
Aspect of medical economics in the selection of
APD or CAPD
Compared with CAPD, APD is more expensive. In a
report from Denmark in 1999, the running cost for APD
was shown to be 123 % of CAPD [16]. The cost of APD
was 139 % of that of CAPD in a UK report from the
National Health Service [69]. In Spain, it was reported
that the cost of APD was approximately 136 to 160 % of
CAPD [70]. Japan is not exceptional with regard to theality of life and sleep
source N (CAPD,APD) Duration of
observation
Results
icenter 34 (17, 17) 6 months APD was better for QoL




96 (59, 37) N/A APD was better
le center 18 12 months Ns.
le center 68 (48, 20) N/A Ns.
le center 224 (111, 131) 5 years Ns.
icenter
OSAD)
550 (486, 64) 3 months–3 years Ns.
icenter 76 (48, 28) N/A Ns.
t, NECOSAD Netherlands Cooperative Study on the Adequacy of Dialysis
Mizuno et al. Renal Replacement Therapy  (2016) 2:46 Page 10 of 13expenses associated with APD. Now, as we face an aging
society, annual medical expenses may be further expanded
in the future worldwide [71, 72]. We may need to balance
the medical and social benefits for each individual PD
patient with cost performance. Because APD is signi-
ficantly more expensive than CAPD, when APD is the
preferred choice, it may be better to perform intermittent
PD with APD in order decrease the number of APD
exchanges. However, to perform intermittent PD alterna-
ting with APD, preservation of RRF and control sodium
intake might be required and decrease overall cost as the
result [73].Other advantages and disadvantages of APD
PD patients often prefer APD because another advantage
is the lessened amount of time required from caregivers
[14, 74]. Particularly, APD may be a good choice for
caregivers of disabled PD patients [74]. On the other
hand, manufacturer’s instructions for handling of cyclers
may be complicated compared with CAPD. Additionally,
if a natural disaster occurs and lifelines including electri-
city are stopped, CAPD can work more easily than
hemodialysis [75, 76]. When the great East Japan earth-
quake happened and the delivery of both electrical
supply and water supply stopped, PD patients could still
continue CAPD therapy [77]. However, cyclers require
electricity because they do not have batteries. Therefore,
CAPD is more efficient during natural disasters, compared
with APD. Cyclers for APD are generally heavy and
require delicate precision and are thus not suitable for
easy carrying. Making space for a cycler and its related
equipment in a patient’s house is required to initiate APD.Advantages of APD for children
Until now, there have not been enough reports to recom-
mend selection between APD and CAPD. Generally,
induction of APD may be considered in children with
ESRD, especially small children who are cared for by their
family [66] and can attend school without the need to per-
form bag exchanges [78]. Comparing children on CAPD
with children on CCPD with a cycler, the removal of
creatinine, urea, and phosphates is similar and dependent
on dwell time and PD volume [66]. To decrease the
incidence of peritonitis in younger children, Lee et al.
reported that APD was better than CAPD [79]. Therefore,
APD may also be important to decrease the risk of bag
change contamination for younger children or their care-
givers. In contrast, Roszkowska-Blaim et al. showed that
RRF was preserved in CAPD more than in APD in
children on PD [80]. As another interesting point, analysis
of health-related QoL of caregivers, such as patients’
parents, was reported. However, even if using APD, it was
commented that children’s parents might still have feltphysiological and emotional stressrelated to supporting
their children [81].
Briefly, as the 2011 NICE guideline in the UK recom-
mends, APD may be offered for children, especially those
with low RRF [82]. However, it is important to keep in
mind that APD may allow reduction of RRF more rapidly
than CAPD.
Expectations for APD in the future
A first-generation cycler, the Pac-X cycler II (Baxter), was
too large for Japanese houses. After that, cycler machines
for APD became more compact and were also functionally
improved. In Japan, the home APD systems YUME and
YUME plus, My home PICO® APD system, PD-mini Neo
APD system, and Sleepsafe® APD system were developed
by Baxter Limited, TERUMO Co. (Tokyo, Japan), JMS Co.
(Tokyo, Japan) and Fresenius Medical Care Japan (Tokyo,
Japan), respectively. Recent cycler machines used in Japan
are able to store APD medical records, monitor the time
course, and review it later, and the cycler machine can
output measurements of body weight and blood pressure
(APD system PD-Mini Neo, JMS Co.). However, the
manufacturer’s information is still complicated and PD
patients are required to learn these procedures when a
cycler machine is introduced. It might be especially diffi-
cult to introduce a cycler machine for disabled patients,
especially those with blindness or hearing loss, as well as
with older patients. In order to induce APD for patients
with hearing loss, a telemetry system as a communication
tool might be useful [83].
As a future cycler machine, Bieber et al. described the
potential development of a cycler for APD that should
be simpler to use and which has a large touchscreen,
sterile connecting system, voice operated controls, a data
sharing function between patients and medical staff, im-
proved safety, and better cost performance [7]. In Japan,
Nakamoto proposed a telemedicine system to manage
outpatients on PD therapy at home [84]. In the future, a
remote-controlled cycler machine may be developed.
At present, many machines are improving worldwide.
Hopefully in the future, a cycler machine for APD will be
developed that would enable the user to set everything
automatically with one touch, and no complicated proce-
dures for how to use the cycler machine will need to be
learned.
Conclusions
At this moment, we still have not had enough evidence to
say which is better, APD or CAPD, for every patient on
PD therapy; and patient and physician preference may be
important in choosing APD. We still need to consider
which may be better between APD and CAPD on an indi-
vidual basis based on medical, socioeconomic, and emo-
tional aspects. Clinically, APD may be a better choice in
Mizuno et al. Renal Replacement Therapy  (2016) 2:46 Page 11 of 13infants and young children, although more supporting
data is needed. Assisted APD may be a better choice for
older patients who require caregiver support. It is also
important to consider each patient’s preference in the
decision to introduce the cycler for APD.
Abbreviations
APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal
dialysis; CCPD, continuous cycling peritoneal dialysis; ESRD, end-stage renal
disease; PD, peritoneal dialysis; PDF, peritoneal dialysate fluid; PET, peritoneal
equilibration test; PKD, polycystic kidney disease; QoL, quality of life; RRF,
residual renal function; SAS, sleep apnea syndrome
Acknowledgements
The authors thank Dr. M. Nakayama and Dr. M. Kubota for the opportunity to
write this review article.
Funding
This work was supported by the 21th annual meeting of the Japanese
Society for Peritoneal Dialysis.
Availability of data and materials
None.
Authors’ contributions
MM designed and drafted the manuscript. YS, FA and YI helped to draft the
manuscript. All authors read and approved the final manuscript.
Competing interests
Mizuno M, Suzuki Y, and Ito Y worked in the Department of Renal
Replacement Therapy as positions endowed by Baxter Japan at Nagoya
University Graduate School of Medicine.
Consent for publication
All authors have contributed for this manuscript. This manuscript has been
read and approved for submission by all authors and is not under review
elsewhere.
Ethics approval and consent to participate
Not available because this manuscript is a review.
Received: 9 May 2016 Accepted: 21 July 2016
References
1. Tenckhoff H, Schechter H. A bacteriologically safe peritoneal access device.
Trans Am Soc Artif Intern Organs. 1968;14:181–7.
2. Boen ST, Mion CM, Curtis FK, Shilipetar G. Periodic peritoneal dialysis using
the repeated puncture technique and an automated cycling machine.
Trans Amer Soc Artif Int Oegans. 1964;10:409–14.
3. Tenckhoff H, Meston B, Shilipetar G. A simplified automatic peritoneal
dialysis system. Trans Am Soc Artif Intern Organs. 1972;18:436–40.
4. Drukker W. 21: Peritoneal dialysis: a historical review, 2nd, revised and
enlarged edition edn. Dordrecht: Martinus Nijhoff Publishers; 1986.
5. Oreopoulos DG. Ambulatory peritoneal dialysis. Lancet. 1978;23:686–7.
6. Sweeny J, Bernardo AA. Chaper 4D Bater Travenol hemodialys and
peritoneal dialysis devices. Singapore: World Scientific Publishing Co.; 2012.
7. Bieber SD, Burkart J, Golper TA, Teitelbaum I, Mehrotra R. Comparative
outcomes between continous ambulatory and automated peritoneal
dialysis: a narrative review. Am J Kidney Dis. 2014;63:1027–37.
8. Sanchez AR, Madonia C, Rascon-Pacheco RA. Improved patient/technique
survival and peritonitis rates in patients treated with automated peritoneal
dialysis when compared to continuous ambulatory peritoneal dialysis in a
Mexican PD center. Kidney Int. 2008;108:S76–80.
9. Mehrotra R. Long-term outcomes in automated peritoneal dialysis: similar or
better than in continuous amburatory peritoneal dialysis? Perit Dial Int.
2009;29:S111–4.
10. Kwan BC, Chow KM, Ma TK, Yu V, Law MC, Leung CB, Li PK, Szeto CC.
Automated peritoneal dialysis in Hong Kong: there are two distinct groups
of patients. Nephrology. 2013;18:356–64.11. Balasubramanian G, McKitty K, Fan SLS. Comparing automated peritoneal
dialysis with continous amburatory peritoneal dialysis: survival and quality
of life differences? Nephrol Dial Transplant. 2011;26:1702–8.
12. Beduschi GC, Figueiredo AE, Olandoski M, Pecoits-Filho R, Barretti P,
de Moraes TP, all centers that contributes to the BRAZPD. Automated
peritoneal dialysis is associated with better survival rates compared to
continuous ambulatory peritoneal dialysis: a propensity score matching
analysis. Plos One. 2015;10:e0134047.
13. Johnson DW, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins KJ,
Bannister KM, Badve SV. Superior survival of high transporters treated with
automated versus continous amburatory peritoneal dialysis. Nephrol Dial
Transplant. 2010;25:1973–9.
14. Virga G. A comparison between continous ambulatory and automated
peritoneal dialysis. J Nephrol. 2013;26:S140–58.
15. de Fijter CW, Oe LP, Nauta JJ, van der Meulen J, Verbrugh HA, Verhoef J,
Donker AJ. Clinical efficacy and morbidity associated with continuous cyclic
compared with continuous ambulatory peritoneal dialysis. Ann Intern Med.
1994;120:264–71.
16. Bro S, Bjorner JB, Tofte–Jensen P, Klem S, Almtoft B, Danielsen H, Meincke
M, Friedberg M, Feldt–Rasmussen B. A Prospective, randomized multicenter
study comparing and APD and CAPD treatment. Perit Dial Int.
1999;19:526–33.
17. Nakayama M, Kasai K, Imai H, TRM-280 Study Group. Novel low Na
peritoneal dialysis solutions designed to optimize Na gap of effluent:
kinetics of Na and water removal. Perit Dial Int. 2009;29:528–35.
18. Rodríguez-Carmona A, Miguel Pérez Fontán M. Soudium removal in
patients undergoing CAPD and automated peritoneal dialysis. Perit Dial Int.
2002;22:705–13.
19. Boudville NC, Cordy P, Millman K, Fairbairn L, Sharma A, Lindsay R, Blake G.
Blood pressure, volume, and sodium control in an automated peritoneal
dialysis population. Perit Dial Int. 2007;27:537–43.
20. Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y. Superior dialytic
clearance of B2-microglobulin and p-cresol by high-flux hemodialysis as
compared to peritoneal dialysis. Kidney Int. 2006;70:794–9.
21. Lee SK, Kim DJ, Moon JH, et al. Peritoneal transport characteristics and
pertoneal clearance of beta2-microglobulin. Korean J Nephrol.
1999;18:599–605.
22. Hiroshige K, Yuu K, Soejima M, Takasugi M, Kuroiwa A. Rapid decline of
residual renal function in patients on automated peritoneal dialysis.
Perit Dial Int. 1996;16:307–15.
23. Eloot S, Vanholder R, Dequidt C, Van Biesen W. Removal of different classes
of uremic toxins in APD vs CAPD: a randomized cross-over study.
Perit Dial Int. 2015;35:436–42.
24. Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and
mortality risk in hemodialysis patients. Am J Kidney Dis. 2001;38:85–90.
25. Lu YH, Hwang JC, Jiang MY, Wang CT. Comparison of the impact of “fast
decline” in residual renal function and "initial anuria" on long-term
outcomes in CAPD patients. Perit Dial Int. 2015;35:172–9.
26. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, Sanderson JE. Inflammation,
residual kidney function, and cardiac hypertrophy are interrelated and
combine adversely to enhance mortality and cardiovascular death risk of
peritoneal dialysis patients. J Am Soc Nephrol. 2004;15:2186–94.
27. Viglino G, Neri L, Barbieri S. Incremental peritoneal dialysis: effects on the
choice of dialysis modality, residual renal function and adequacy.
Kidney Int Suppl. 2008;108:S52–5.
28. Li PK, Cheng YL. Therapeutic options for preservation of residual renal
function in patients on peritoneal dialysis. Kidney Int. 2007;27:S158–63.
29. Marrón B, Remón C, Pérez-Fontán M, Quirós P, Ortíz A. Benefits of
preserving residual renal function in peritoneal dialysis. Kidney Int.
2008;73:S42–51.
30. Nongnuch A, Assanatham M, Panorchan K, Davenport A. Strategies for
preserving residual renal function in peritoneal dialysis patients.
Clin Kisney J. 2015;8:202–11.
31. Neri L, Viglino G, Cappelletti A, Gandolfo C, Barbieri S. Incremental dialysis
with automated peritoneal dialysis. Adv Perit Dial. 2003;19:93–6.
32. Pérez Fontán M, Remón Rodríguez C, Borràs Sans M, Sánchez Álvarez E,
da Cunha NM, Quirós Ganga P, López-Calviño B, Rodríguez Suárez C,
Rodriguez-Carmona A. Compared decline of residual kidney function in
patients treated with automated peritoneal dialysis and continuous
ambulatory peritoneal dialysis: a multicenter study. Nephron Clin Pract.
2015;128:352–60.
Mizuno et al. Renal Replacement Therapy  (2016) 2:46 Page 12 of 1333. Rabindranath KS, Adams J, Ali TZ, Daly C, Vale L, Macleod AM. Automated
vs continuous ambulatory peritoneal dialysis: a systematic review of
randomized controlled trials. Nephrol Dial Transplant. 2007;22:2991–8.
34. Lan PG, Johnson DW, McDonald SP, Boudville N, Borlace M, Badve SV, Sud
K, Clayton PA. The association between peritoneal dialysis modality and
peritonitis. Clin J Am Soc Nephrol. 2014;9:1091–7.
35. Mizuno M, Ito Y, Suzuki Y, Sakata F, Saka Y, Hiramatsu T, Tamai H, Mizutani
M, Naruse T, Ohashi N et al. Recent analysis of status and outcomes of
peritoneal dialysis in the Tokai area of Japan: the second report of the Tokai
peritoneal dialysis registry. Clin Exp Nephrol. 2016, in press.
36. Rüger W, van Ittersum FJ, Comazzetto LF, Hoeks SE, ter Wee PM. Similar
peritonitis outcome in CAPD and APD patients with dialysis modality
continuation during peritonitis. Perit Dial Int. 2011;31:39–47.
37. Diaz-Buxo JA, Crawford TL, Bailie GR. Peritonitis in automated peritoneal
dialysis: antibiotic therapy and pharmacokinetics. Perit Dial Int.
2001;21:S197–201.
38. Manley HJ, Bailie GR. Treatment of peritonitis in APD: pharmacokinetic
principles. Semin Dial. 2002;15:418–21.
39. Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, Johnson
DW, Kuijper EJ, Lye WC, Salzer W, et al. Peritoneal dialysisrelated infections
recommendations: 2010 update. Perit Dial Int. 2010;30:393–423.
40. Bargman JM. Complications of peritoneal dialysis related to increased
intra-abdominal pressure. Kidney Int. 1993;40:S75–80.
41. del Peso G, María Auxiliadora Bajo MA, Costero O, Hevia C, Gil F, Díaz C,
Aguilera A, Selgas R. Risk factors for abdominal wall complications in
peritoneal dialysis patients. Perit Dial Int. 2003;249–254.
42. Twardowski ZJ, Khanna R, Nolph KD, Scalamogna A, Metzler MH, Schneider
TW, Prowant BF, Ryan LP. Intraabdominal pressures during natural activities
in patients treated with continuous ambulatory peritoneal dialysis.
Nephron. 1986;44:129–35.
43. Dejardin A, Robert A, Goffin E. Intraperitoneal pressure in PD patients:
relationship to intraperitoneal volume, body size and PD-related
complications. Nephrol Dial Transplant. 2007;22:1437–44.
44. Hussain SI, Bernardini J, Piraino B. The risk of hernia with large exchange
volumes. Adv Perit Dial. 1998;14:105–7.
45. Modi KB, Grant AC, Garret A, Rodger RS. Indirect inguinal hernia in CAPD
patients with polycystic kidney disease. Adv Perit Dial. 1989;5:84–6.
46. Morris–Stiff G, Coles G, Moore R, Jurewicz A, Lord R. Abdominal wall hernia
in autosomal dominant polycystic disease. Br J Surg. 1997;84:615–7.
47. Hadimeri H, Johansson A-C, Haraldsson B, Nyberg G. CAPD in patients with
autosomal dominant polycystic kidney disease. Perit Dial Int. 1998;18:429–32.
48. del Peso G, Auxiliadora Bajo MA, Costero O, Hevia C, Gil F, Díaz C, Aguilera
A, Selgas R. Risk factors for abdominal wall complications in peritoneal
dialysis patients. Perit Dial Int. 2003;23:249–54.
49. Tast C, Kuhlmann U, Stölzing H, Alscher D, Mettang T. Continuing CAPD
after herniotomy. EDTNA ERCA J. 2002;28:173–5.
50. Shah H, Chu M, Bargman JM. Perioperative management of peritoneal
dialysis patients undergoing hernia surgery without the use of interim
hemodialysis. Perit Dial Int. 2006;26:684–7.
51. Kumano K, Sakai T, Yamashita A. A adequate volume of infusion and
frequency of dialysate exchange on automated peritoneal dialysis.
Jpn J Artif Organs. 1992;21:893–7.
52. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular
risk factors in end-stage renal disease. Kidney Int. 2003;85:S105–10.
53. Iseki K, Tsuruya K, Kanda E, Nomura T, Hirakata H. Effects of sleepiness on
survival in Japanese hemodialysis patients: J-DOPPS study. Nephron Clin
Pract. 2014;128:333–40.
54. Ezzat H, Mohab A. Prevalence of sleep disorders among ESRD patients.
Ren Fail. 2015;37:1013–9.
55. Mavanur M, Sanders M, Unruh M. Sleep disordered breathing in patients
with chronic kidney disease. Indian J Med Res. 2010;131:277–84.
56. Parati G, Ochoa JE, Bilo G, Mattaliano P, Salvi P, Kario K, Lombardi C.
Obstructive sleep apnea syndrome as a cause of resistant hypertension.
Hypertens Res. 2014;37:601–13.
57. Shamsuzzaman AS, Somers VK, Knilans TK, Ackerman MJ, Wang Y, Amin RS.
Obstructive sleep apnea in patients with congenital long QT syndrome:
implications for increased risk of sudden cardiac death. Sleep. 2015;38:1113–9.
58. Tang SC, Lam B, Ku PP, Leung WS, Chu CM, Ho YW, Ip MS, Lai KN.
Alleviation of sleep apnea in patients with chronic renal failure by nocturnal
cycler-assisted peritoneal dialysis compared with conventional continuous
ambulatory peritoneal dialysis. J Am Soc Nephrol. 2006;17:2607–16.59. Tang SC, Lam B, Yao TJ, Leung WS, Chu CM, Ho YW, Ip MS, Lai KN. Sleep
apnea is a novel risk preditor of cardiovasular morbidity and death in
patients receiving peritoneal dialysis. Kidney Int. 2010;77:1031–8.
60. Winchester JF. Peritoneal dialysis and pulmonary function.
Chest. 1984;88:806–7.
61. Khanna R, Nolph KD, Oreopulos DG. Techniques prescriptions and
indications. In: Khanna R, Nolph KD, Oreopoulos DG, editors. The essentials
of peritoneal dialysis. Dordrecht: Academic; 1993. p. 35–44.
62. Singh S, Dale A, Morgan B, Sahebjami H. Pulmonary function tests in
patients on continuous ambulatory peritoneal dialysis. Amsterdam:
Excerpta Medica; 1981.
63. Leblanc M, Ouimet D, Tremblay C, Nolin L. Peritoneal instillation test before
CAPD in a case of severe pulmonary disease. Perit Dial Int. 1995;15:384–7.
64. Winchester JF, Da Silva AMT, Davis W, Weir C, Barnard W, Rakowski TA, et al.
Altered pulmonary function with continuous ambulatory peritoneal dialysis,
vol. 1981. Amsterdam: Excerpta Medica; 1981.
65. Guney I, Solak H, Yazici R, Altintepe L, Kara F, Yeksan M, Turk S. Comparison
of effetcs of automated peritoneal dialysis and continuous amburatory
peritoneal dialysis on health-related quality of life, sleep quality, and
depression. Hemodial Int. 2010;14:515–22.
66. Balfe JW. Comparison of CAPD and CCPD in children and their limitations.
Saudi J Kidney Dis Transplant. 1994;5:173–8.
67. de Wit GA, Merkus MP, Krediet RT, de Charro FT. A comparison of quality
of life of patients on automated and continuous ambulatory peritoneal
dialysis. Perit Dial Int. 2001;21:306–12.
68. Sunder S, Kalra OP, Nashine S, Waghmare V, Ruchi R. Comparative study of
adequacy of dialysis and health-related quality of life in patients on CAPD
and APD. Perit Dial Int. 2008;28:542–4.
69. Baboolal K, McEwan P, Sondhi S, Spiewanowski P, Wechowski J, Wilson K.
The cost of renal dialysis in a UK setting—a multicentre study.
Nephrol Dial Transplant. 2008;23:1982–9.
70. Lamas Barreiro JM, Alonso Suárez M, Saavedra Alonso JA, Gándara Martínez
A. Costs and added value of haemodialysis and peritoneal dialysis
outsourcing agreements. Nefrologia. 2011;31:656–63.
71. Brunkhorst R, Wrenger E, Krautzig S, Ehlerding G, Mahiout A, Koch KM.
Clinical experience with home automated peritoneal dialysis.
Kidney Int. 1994;46:S25–30.
72. Johnson D, Brown F, Lammi H, Walker R. Caring for Australians with renal
impairment (CARI). The CARI guidelines. Dialysis adequacy (PD) guidelines.
Nephrology. 2005;10:S81–S107.
73. Guest S, Akonur A, Ghaffari A, Sloand J, Leypoldt JK. Intermittent peritoneal
dialysis: urea kinetic modeling and implications of residual kidney function.
Perit Dial Int. 2012;32:142–8.
74. Dombros N, Dratwa M, Feriani M, Gokal R, Heimbürger O, Krediet R, Plum J,
Rodrigues A, Selgas R, Struijk D, et al. European best practice guidelines for
peritoneal dialysis. 6 Automated peritoneal dialysis. Nephrol Dial Transplant.
2005;20:ix21–3.
75. Kleinpeter MA. Disaster preparedness for dialysis patients. Clin J Am Soc
Nephrol. 2011;6:2337–9.
76. Gray NA, Wolley M, Liew A, Nakayama M. Natural disasters and dialysis care
in the Asia-Pacific. Nephrology. 2015;20:873–80.
77. Kumagai N. Managing children who reqire peritoneal dialysis at the Tohoku
University Hospital department of pediatrics immediately after the Great
Easrern Japan Earthquake. Nihon Shoni Jinzobyo Gakkai Zasshi. 2015;28:134–9.
78. Liakopoulos V, Dombros N. Patient selection for automated peritoneal
dialysis: for whom, when? Perit Dial Int. 2009;29:S102–7.
79. Lee KO, Park SJ, Kim JH, Lee JS, Kim PK, Shin JI. Outcomes of peritonitis in
children on peritoneal dialysis: a 25-year experience at Severance Hospital.
Yonsei Med J. 2013;54:983–9.
80. Roszkowska-Blaim M, Skrzypczyk P, Jander A, Tkaczyk M, Bałasz-Chmielewska
I, Zurowska A, Drozdz D, Pietrzyk JA. The effect of peritoneal dialysis
method on residual renal function in children. Adv Perit Dial. 2012;28:112–9.
81. Kiliś-Pstrusińska K, Wasilewska A, Medyńska A, Bałasz-Chmielewska I,
Grenda R, Kluska-Jóźwiak A, Leszczyńska B, Olszak-Szot I, Miklaszewska M,
Szczepańska M, et al. Psychosocial aspects of children and families of
children treated with automated peritoneal dialysis. Pediatr Nephrol.
2013;28:2157–67.
82. National Institute for health and clinical excellence. Peironeal dialysis.
Perioneal dialysis in the treatment of stage 5 chronic kidney disease. In:
NICE clinical guideline 125 developed by the centre for clinical practice at
NICE. UK: National Institute for health and clinical excellence; 2011.
Mizuno et al. Renal Replacement Therapy  (2016) 2:46 Page 13 of 1383. Sakurada T, Kojima S, Oishi D, Koitabashi K, Shibagaki Y, Kimura K.
Automated peritoneal dialysis for a patient with hearing loss: a case report.
Perit Dial Int. 2015;35:229–35.
84. Nakamoto H. Telemedicine system for patients on contiuous amburatory
peritoneal dialysis. Perit Dial Int. 2007;27:S21–6.
85. Guo A, Mujais S. Patient and technique survival on peritoneal dialysis in the
United States: evaluation in large incident cohorts. Kidney Int Suppl.
2003;88:S3–S12.
86. Badve SV, Hawley CM, McDonald SP, et al. Automated and continuous
ambulatory peritoneal dialysis have similar outcomes. Kidney Int. 2008;73:
480–8.
87. Liao CT, Shiao CC, Huang JW, et al. Predictors of faster decline of residual
renal function in Taiwanese peritoneal dialysis patients. Perit Dial Int.
2008;28 suppl 3:S191–5.
88. Mehrotra R, Chiu YW, Kalantar-Zadeh K, Vonesh E. The outcomes of
continuous ambulatory and automated peritoneal dialysis are similar.
Kidney Int. 2009;76:97–107.
89. Michels WM, Verduijn M, Boeschoten EW, Dekker FW, Krediet RT, Group NS.
Similar survival on automated peritoneal dialysis and continuous
ambulatory peritoneal dialysis in a large prospective cohort. Clin J Am Soc
Nephrol. 2009;4:943–9.
90. Cnossen TT, Usvyat L, Kotanko P, et al. Comparison of outcomes on
continuous ambulatory peritoneal dialysis versus automated peritoneal
dialysis: results from a USA database. Perit Dial Int. 2011;31:679–84.
91. Sun CY, Lee CC, Lin YY, Wu MS. In younger dialysis patients, automated
peritoneal dialysis is associated with better long-term patient and technique
survival than is continuous ambulatory peritoneal dialysis. Perit Dial Int.
2011;31:301–7.
92. Hufnagel G, Michel C, Queffeulou G, Skhiri H, Damieri H, Mignon F. The
influence of automated peritoneal dialysis on the decrease in residual renal
function. Nephrol Dial Transplant. 1999;14:1224–8.
93. Gallar P, Ortega O, Carreno A, Vigil A. Rate of decline in residual renal
function is equal in CAPD and automated peritoneal dialysis patients.
Perit Dial Int. 2000;20:803–5.
94. Hamada C, Osada S, Inoue S, et al. Effects of automated peritoneal dialysis
on residual urinary volume. Perit Dial Int. 2000;20:239–41.
95. Moist LM, Port FK, Orzol SM, et al. Predictors of loss of residual renal
function among new dialysis patients. J Am Soc Nephrol. 2000;11:556–64.
96. Singhal MK, Bhaskaran S, Vidgen E, Bargman JM, Vas SI, Oreopoulos DG.
Rate of decline of residual renal function in patients on continuous
peritoneal dialysis and factors affecting it. Perit Dial Int. 2000;20:429–38.
97. Holley JL, Aslam N, Bernardini J, Fried L, Piraino B. The influence of
demographic factors and modality on loss of residual renal function in
incident peritoneal dialysis patients. Perit Dial Int. 2001;21:302–5.
98. Hidaka H, Nakao T. Preservation of residual renal function and factors
affecting its decline in patients on peritoneal dialysis. Nephrology.
2003;8:184–91.
99. Johnson DW, Mudge DW, Sturtevant JM, et al. Predictors of decline of
residual renal function in new peritoneal dialysis patients. Perit Dial Int.
2003;23:276–83.
100. Rodriguez-Carmona A, Perez-Fontan M, Garca-Naveiro R, Villaverde P,
Peteiro J. Compared time profiles of ultrafiltration, sodium removal, and
renal function in incident CAPD and automated peritoneal dialysis patients.
Am J Kidney Dis. 2004;44:132–45.
101. Michels WM, Verduijn M, Grootendorst DC, et al. Decline in residual renal
function in automated compared with continuous ambulatory peritoneal
dialysis. Clin J Am Soc Nephrol. 2011;6:537–42.
102. Alliapoulos JC, Salusky IB, Hall T. Comparison of continuous cycling
peritoneal dialysis with continuous ambulatory peritoneal dialysis in
children. J Pediatr. 1984;105:721–5.
103. Rodríguez–Carmona A, Fontán MP, Falcón TG, Rivera CF, Valdés F.
A comparative analysis on the incidence of peritonitis and exit-site infection
in CAPD and automated peritoneal dialysis. Perit Dial Int. 1999;19:253–8.
104. Yishak A, Bernardini J, Fried L, Piraino B. The outcome of peritonitis in
patients on automated peritoneal dialysis. Adv Perit Dial. 2001;17:205–8.
105. Oo TN, Roberts TL, Collins AJ. A comparison of peritonitis rates from the
United States Renal Data System database: CAPD versus continuous cycling
peritoneal dialysis patients. Am J Kidney Dis. 2005;45:372–80.
106. Davenport A. Peritonitis remains the major clinical complication of
peritoneal dialysis: the London, UK, peritonitis audit 2002–2003.
Perit Dial Int. 2009;29:297–302.107. Nessim SJ, Bargman JM, Austin PC, Nisenbaum R, Jassal SV. Predictors of
peritonitis in patients on peritoneal dialysis: results of a large, prospective
Canadian database. Clin J Am Soc Nephrol. 2009;4:1195–200.
108. Mizuno M, Ito Y, Tanaka A, Suzuki Y, Hiramatsu H, Watanabe M, et al.
Peritonitis is still an important factor for withdrawal from peritoneal dialysis
therapy in the Tokai area of Japan. Clin Exp Nephrol. 2011;15:727–37.
109. Nishina M, Yanagi H, Kakuta T, Endoh M, Fulagawa M, Takagi A. A 10-year
retrospective cohort study on the risk factors for peritoneal dialysis-related
peritonitis: a single-center study at Tokai University Hospital.
Clin Exp Nephrol. 2014;18:649–54.
110. Losso RL, Minhoto GR, Riella MC. Sleep disorders in patients with end-stage
renal disease undergoing dialysis: comparison between hemodialysis,
continuous ambulatory peritoneal dialysis and automated peritoneal
dialysis. Int Urol Nephrol. 2015;47:369–75.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
